Eksjö (SE) Cancer Clinical Trials

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~42 mi. (Jönköping, Sweden, +144 more cities)

Lanssjukhuset Ryhov ( Site 2103)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~42 mi. (Jönköping, Sweden, +159 more cities)

Laenssjukhuset Ryhov ( Site 1205)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

~42 mi. (Jönköping, Sweden, +209 more cities)

Ryhov Hospital

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~76 mi. (Linköping, Sweden, +176 more cities)

Universitetssjukhuset i Linkoping. ( Site 2222)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types